Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Regeneron Pharmaceuticals : Reports Positive Phase 2 Data for Pozelimab in PNH

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/05/2019 | 09:26am EST

By Colin Kellaher

Regeneron Pharmaceuticals Inc. (REGN) on Thursday reported positive topline phase 2 data for pozelimab in patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria, or PNH.

The Tarrytown, N.Y., biotechnology company, said results from initial six-patient cohort show pozelimab reduced the abnormal destruction of red blood cells, known as hemolysis, with patients achieving normal levels of a blood biomarker of elevated hemolysis called lactate dehydrogenase.

Regeneron said it has initiated the second part of the phase 2 trial, adding that plans for a phase 3 program are underway.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
01/13Novartis to speed access to $10 billion heart drug via NHS deal
RE
01/13REGENERON PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2019 Financia..
AQ
01/13REGENERON PHARMACEUTICALS, INC. : Results of Operations and Financial Condition,..
AQ
01/10REGENERON PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2019 Financia..
PR
01/09REGENERON PHARMACEUTICALS : Announces Encouraging Garetosmab Phase 2 Results in ..
PR
01/08REGENERON PHARMACEUTICALS : Publication Highlights Regeneron's Costimulatory Bis..
PR
2019REGENERON PHARMACEUTICALS : Announces presentation at the 38th annual j.p. morga..
AQ
2019REGENERON PHARMACEUTICALS : Announces Presentation at the 38th Annual J.P. Morga..
PR
2019GLAXOSMITHKLINE : Study Shows Blood Cancer Drug Works in Heavily Treated Patient..
DJ
2019REGENERON PHARMACEUTICALS : Society for Science and the Public Announces Regener..
AQ
More news
Financials (USD)
Sales 2019 7 803 M
EBIT 2019 2 281 M
Net income 2019 1 987 M
Finance 2019 5 503 M
Yield 2019 -
P/E ratio 2019 21,9x
P/E ratio 2020 16,6x
EV / Sales2019 4,70x
EV / Sales2020 4,18x
Capitalization 42 152 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 394,57  $
Last Close Price 385,57  $
Spread / Highest target 32,3%
Spread / Average Target 2,33%
Spread / Lowest Target -16,0%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Executive VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS4.07%42 376
GILEAD SCIENCES-2.74%81 222
VERTEX PHARMACEUTICALS7.56%59 080
WUXI APPTEC CO., LTD.3.66%22 772
GENMAB2.36%14 701
BEIGENE, LTD.1.26%12 922